Abstract
Background
A limited sampling strategy (LSS) for estimating the area under the curve (AUC) of the prolonged-release formulation of tacrolimus (tacrolimusPR) is not available in pediatric patients, although the method is of real benefit to children. The objective of this study was to develop and validate a reliable and clinically applicable LSS using Bayesian estimation for estimating tacrolimusPR AUC in pediatric kidney transplant patients
Methods
The original tacrolimus pharmacokinetic dataset consisted of 22 full profiles from 22 pediatric kidney transplant patients. The Bayesian estimation method was used to develop the LSS. External validation was performed in an independent validation group which consisted of 20 full pharmacokinetic profiles from 12 pediatric kidney transplant patients.
Results
Bayesian estimator using C0h C2h and C3h gave the best predictive performance with a mean prediction error of 2.2 % in the external validation dataset. There was no correlation between the prediction error and age. The Bland–Altman analysis showed that the mean difference between the reference and Bayesian-estimated AUC0-24 was 3.5 (95 % confidence interval −3.5–10.5) ng h/mL
Conclusions
A reliable and clinically applicable LSS for estimating AUC0–24 of tacrolimusPR was determined and validated in children. The prediction was unbiased and precise. It can be used as a routine procedure to perform AUC-based tacrolimusPR dosage optimization in pediatric renal transplant patients.
This is a preview of subscription content, log in via an institution to check access.
References
European Medicines Agency. Advagraf 0.5 mg prolonged-release hard capsules: summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000712/WC500022234.pdf. Assessed 22 Mar 2012
European Medicines Agency. Advagraf: scientific discussion. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000712/WC500022237.pdf. Assessed in 22 Mar 2012
First MR (2008) First clinical experience with the new once-daily formulation of tacrolimus. Ther Drug Monit 30(2):159–166
Heffron TG, Pescovitz MD, Florman S et al (2007) Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients. Am J Transplant 7(6):1609–1615
Zhao W, Fakhoury M, Baudouin V, Maisin A, Deschênes G, Jacqz-Aigrain E (2011) Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients. Ther Drug Monit 33(6):681–687
Ting LS, Villeneuve E, Ensom MH (2006) Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit 28(3):419–430
Filler G, Feber J, Lepage N, Weiler G, Mai I (2002) Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 6(5):411–418
Delaloye JR, Kassir N, Lapeyraque AL et al (2011) Limited sampling strategies for monitoring tacrolimus in pediatric liver transplant recipients. Ther Drug Monit 33(4):380–386
Benkali K, Rostaing L, Premaud A et al (2010) Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 49(10):683–692
Saint-Marcoux F, Debord J, Undre N, Rousseau A, Marquet P (2010) Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimusonce-daily formulation. Ther Drug Monit 32(2):129–135
Zhao W, Fakhoury M, Jacqz-Aigrain E (2010) Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit 32(6):688–699
Zhao W, Elie V, Roussey G et al (2009) Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86(6):609–618
Zhao W, Fakhoury M, Baudouin V et al. (2012) Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol. doi: 10.1007/s00228-012-1330-6
van der Meer AF, Marcus MA, Touw DJ, Proost JH, Neef C (2011) Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 33(2):133–146
Proost JH (2007) Validation of limited sampling models (LSM) for estimating AUC in therapeutic drug monitoring––is a separate validation group required? Int J Clin Pharmacol Ther 45(7):402–409
Acknowledgments
We thank all of the children and their families who participated in this study. We also acknowledge the local clinical investigators (Marc Fila, Claire Dossier, Theresa Kwon and Daolun Zhang) for conducting the study and technicians (Christel Grondin, Michel Popon, Samira Benakouche and Yves Médard) for technical support. This work was supported by Global Research in Paediatrics Network of Excellence (GRIP, EU-funded FP7 project, Grant Agreement no. 261060).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhao, W., Maisin, A., Baudouin, V. et al. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. Eur J Clin Pharmacol 69, 1181–1185 (2013). https://doi.org/10.1007/s00228-012-1457-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-012-1457-5